-
Article
Open AccessBeta 1 integrin signaling mediates pancreatic ductal adenocarcinoma resistance to MEK inhibition
Pancreatic cancer, one of the deadliest human malignancies, has a dismal 5-year survival rate of 9%. KRAS is the most commonly mutated gene in pancreatic cancer, but clinical agents that directly target mutant KR...
-
Article
ATDC mediates a TP63-regulated basal cancer invasive program
Basal subtype cancers are deadly malignancies but the molecular events driving tumor lethality are not completely understood. Ataxia-telangiectasia group D complementing gene (ATDC, also known as TRIM29), is high...
-
Article
A surgical orthotopic approach for studying the invasive progression of human bladder cancer
The invasion of bladder cancer into the sub-urothelial muscle and vasculature are key determinants leading to lethal metastatic progression. However, the molecular basis is poorly understood, partly because of...
-
Reference Work Entry In depth
Pancreatic Cancer Stem Cells
Cancer stem cells (CSCs) are a distinct subpopulation of cells within a tumor that are capable of self-renewal and producing differentiated progeny. These cells appear to be more resilient to treatment than bu...
-
Living Reference Work Entry In depth
Pancreatic Cancer Stem Cells
Cancer stem cells (CSCs) are a distinct subpopulation of cells within a tumor that are capable of self-renewal and producing differentiated progeny. These cells appear to be more resilient to treatment than bu...
-
Chapter
Molecular Targeted Therapies in Pancreatic Cancer
Pancreatic cancer, one of the deadliest malignancies, is a complex disease consisting of heterogeneous cancer cells with deregulated signaling pathways and a myriad of microenvironment cells, including infiltr...
